前列腺癌 (PCa) 是男性癌症相关死亡的第二大原因。诊断 PCa 依赖于称为诊断生物标记的分子标记，而预后生物标记用于识别 PCa 治疗中涉及的关键蛋白质。本研究旨在收集 PCa 相关基因并评估它们作为 PCa 诊断或预后生物标志物的潜力。汇编了 PubMed 1936 年 5 月至 2020 年 12 月期间 152,064 个 PCa 相关数据的语料库。此外，从国家生物技术信息中心 (NCBI) 数据库收集了 4199 个与 PCa 术语相关的基因。使用 pubmed.mineR 提取 PubMed 语料库数据来识别 PCa 相关基因。使用各种工具进行网络和通路分析，例如 STRING、DAVID、KEGG、MCODE 2.0、cytoHubba 应用程序、CluePedia 和 ClueGO 应用程序。使用随机森林、支持向量机、神经网络算法和考克斯比例风险模型来识别重要的标记基因。这项研究报告了 3062 个独特的 PCa 相关基因以及 2518 个相应的独特 PMID。 PubMed 中鉴定了 IL6、MAPK3、JUN、FOS、ACTB、MYC 和 TGFB1 等诊断标记物，同时突出显示了 ACTB 和 HDAC1 等预后标记物。这表明 PubMed 数据提供的潜在目标基因超过了 NCBI 数据库中的目标基因。© 2024。作者获得 Springer Science Business Media, LLC（Springer Nature 的一部分）的独家许可。

Prostate cancer (PCa) ranks as the second leading cause of cancer-related deaths in men. Diagnosing PCa relies on molecular markers known as diagnostic biomarkers, while prognostic biomarkers are used to identify key proteins involved in PCa treatments. This study aims to gather PCa-associated genes and assess their potential as either diagnostic or prognostic biomarkers for PCa. A corpus of 152,064 PCa-related data from PubMed, spanning from May 1936 to December 2020, was compiled. Additionally, 4199 genes associated with PCa terms were collected from the National Center of Biotechnology Information (NCBI) database. The PubMed corpus data was extracted using pubmed.mineR to identify PCa-associated genes. Network and pathway analyses were conducted using various tools, such as STRING, DAVID, KEGG, MCODE 2.0, cytoHubba app, CluePedia, and ClueGO app. Significant marker genes were identified using Random Forest, Support Vector Machines, Neural Network algorithms, and the Cox Proportional Hazard model. This study reports 3062 unique PCa-associated genes along with 2518 corresponding unique PMIDs. Diagnostic markers such as IL6, MAPK3, JUN, FOS, ACTB, MYC, and TGFB1 were identified, while prognostic markers like ACTB and HDAC1 were highlighted in PubMed. This suggests that the potential target genes provided by PubMed data outweigh those in the NCBI database.© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.